

14. **(Previously Presented):** The composition as in claim 11 wherein the Formula 1 compound has a specific activity of about 20 Ci/mmol or greater.

15. **(Previously Presented):** The composition as in claim 11 wherein the Formula 1 compound is a ligand for the TRP-M8 receptor.

16. **Cancelled.**

17. - 22. **(Withdrawn).**


23. – 35. **Cancelled.**

REMARKS

The examiner has allowed claims 1-5, 7 and 11-15. Claims 17 - 22 have been withdrawn from consideration as being drawn to a non-elected invention/species. Claims 8-10, 16, 23, 25, 26, 28 and 30-33 have been rejected. Since by the present response applicant has cancelled claims 8-10, 16, 23, 25, 26, 28 and 30-33, **all** the pending claims have been allowed. Therefore an early indication of allowance is appropriate and is requested.

Respectfully submitted,

Wei.10



Edward T. Wei, Applicant
Cragmont Pharmaceuticals, LLC
480 Grizzly Peak Blvd., Berkeley, CA 94708
510/524-0414